We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.70 | 2.84% | 61.50 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 118 | 08:00:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
From Apr 2022 to Apr 2024
TIDMTRX
RNS Number : 3905V
Tissue Regenix Group PLC
05 April 2023
Tissue Regenix Group plc
('Tissue Regenix' or the 'Company')
CEO and CFO Share Purchases
Tissue Regenix (AIM: TRX), the regenerative medical device company, announces that on 4 April 2023, Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer each purchased 1,428,570 of the Company's ordinary shares of 0.1p each ("Ordinary Shares").
Hot Features
Premium
Name Title Number of Resulting Percentage
Ordinary beneficial of Company's
Shares purchased interest in Total Voting
the Company's Rights
Ordinary Shares
Daniel Lee Chief Executive Officer 1,428,570 8,690,770 0.12%
David Cocke Chief Financial Officer 1,428,570 7,120,570 0.10%
------------------------- ------------------ ----------------- --------------
For more information:
Tissue Regenix Group plc www.tissueregenix.com David Cocke, Chief Financial Officer Via Walbrook PR finnCap Ltd (Nominated Adviser and Broker) Emily Watts/Geoff Nash/George Dollemore - Corporate Finance Nigel Birks/Harriet Ward - ECM Walbrook PR (Financial PR & IR) Tel: +44(0)20 7933 8780 Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation technology ('dCELL(R)') removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies(R), a biotech company that specialises in regenerative medicine and is dedicated to the development of high quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight(R)'s human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Daniel Lee
--------------------------------------- ---------------------------------------
Reason for the notification
2
--------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------------------------- ---------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------------------------- ---------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1p each
financial instrument,
type of instrument
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
0.5700p 500,000
----------------- -----------------
0.5650p 928,570
----------------- -----------------
d) Aggregated information
- Aggregated volume 1,428,570
- Price GBP8,096.42
e) Date of the transaction 4 April 2023
--------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------------------- ---------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name David Cocke
--------------------------------------- ---------------------------------------
Reason for the notification
2
--------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------------------------- ---------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------------------------- ---------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1p each
financial instrument,
type of instrument
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
0.5700p 500,000
----------------- -----------------
0.5650p 928,570
----------------- -----------------
d) Aggregated information
- Aggregated volume 1,428,570
- Price GBP8,096.42
e) Date of the transaction 4 April 2023
--------------------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------------------- ---------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKZGGDRDKGFZM
(END) Dow Jones Newswires
April 05, 2023 02:00 ET (06:00 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
